VIDEO: Aptiv Solutions CEO Discusses Clinical Trials Guidelines, Unmet Need

Aside from re-defined financing structures, the most important issue facing life sciences EGCs is the need to increase clinical trial efficiency and productivity so that development budgets are used prudently to support products that have the best chance of market success. Speaking to OneMedTV during OneMedForum this past January, Donnelly discussed current changes that will impact the future of product development and the central role that innovative trial design will play in this.

Read more »

The Briefing Room, August 24: The Week That Was in Microcap Biotech Stocks

OneMedPlace introduces a new series, “The Briefing Room”, capturing the past week’s most important developments in microcap life sciences indexes. This week, we feature Star Scientific, Kips Bay Medical, XOMA and Stellar Pharmaceuticals.

Read more »

Bulls, Bears: Hot Nanocap CNS Companies

In Part II of our special report on the state of companies operating in central nervous system disease in the public markets, we look at one of the most promising nanocap companies we believe is ready to skyrocket.

Read more »

Bulls, Bears: The State of CNS Companies in the Public Markets

Historically, the biotech sector has found it difficult to navigate CNS. It also has affected shareholders in numerous enterprises, with the perception that billions of investor dollars have already been wasted on overreaching and misunderstood technologies.

Read more »

EpiCept’s Ceplene Product Receives Marketing Auth. by European Commission

Ceplene is administered for maintenance of first remission in patients with AML, the most common type of Leukemia in adults.

Read more »

Protected: VIDEO: Talking JOBS Act with Christine Jacobs, SEC Advisory Committee Chair

There is no excerpt because this is a protected post.

Read more »

Blood Tests Can Enable Early Cancer Diagnosis

Scientists have yet to find the magic cure for cancer, but they may have found a way to beat it at its own game.

Read more »

Encouraging Fragile X Data for Seaside Therapeutics

Seaside Therapeutics reported encouraging results from the largest randomized study conducted to date in patients with Fragile X syndrome.

Read more »

Resverlogix to Begin Phase II Atherosclerosis Trial

Canadian biopharmaceutical company Resverlogix has commenced a Phase II clinical trial for RVX-208, its small molecule therapy for the treatment of atherosclerosis in patients with stable coronary artery disease.

Read more »

Cohera Receives Approval for Surgical Adhesive Trial

Pittsburgh-based Cohera Medical has received approval to begin clinical trials on its TissuGlu surgical adhesive in Europe.

Read more »